Jump Financial LLC Sells 6,027 Shares of BioNTech SE (NASDAQ:BNTX)

Jump Financial LLC reduced its position in shares of BioNTech SE (NASDAQ:BNTX) by 55.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,791 shares of the company’s stock after selling 6,027 shares during the period. Jump Financial LLC’s holdings in BioNTech were worth $1,072,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in BNTX. Firestone Capital Management acquired a new stake in BioNTech during the 2nd quarter worth approximately $29,000. MV Capital Management Inc. acquired a new position in shares of BioNTech during the second quarter worth $41,000. Mark Sheptoff Financial Planning LLC bought a new stake in shares of BioNTech in the second quarter worth $45,000. Advisory Services Network LLC bought a new position in BioNTech during the 2nd quarter worth $47,000. Finally, Clearstead Advisors LLC acquired a new position in BioNTech during the 2nd quarter worth about $48,000. 14.49% of the stock is owned by institutional investors.

BioNTech stock opened at $249.40 on Thursday. The firm has a market capitalization of $60.48 billion, a price-to-earnings ratio of 13.05 and a beta of -1.59. The firm’s fifty day moving average price is $331.44 and its two-hundred day moving average price is $249.12. BioNTech SE has a 1-year low of $75.35 and a 1-year high of $464.00. The company has a current ratio of 2.67, a quick ratio of 2.57 and a debt-to-equity ratio of 0.04.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Sunday, August 8th. The company reported $10.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.35 by $2.42. The business had revenue of $5.31 billion during the quarter, compared to the consensus estimate of $3.27 billion. BioNTech had a return on equity of 159.73% and a net margin of 52.48%. The company’s quarterly revenue was up 12599.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.38) EPS. On average, research analysts forecast that BioNTech SE will post 37.71 EPS for the current year.

Several analysts recently commented on the company. UBS Group set a $300.00 target price on BioNTech in a report on Thursday, September 23rd. TheStreet upgraded shares of BioNTech from a “c” rating to a “b-” rating in a research report on Monday. Berenberg Bank set a $400.00 target price on shares of BioNTech in a report on Tuesday, October 5th. HC Wainwright reiterated a “hold” rating and set a $330.00 price target on shares of BioNTech in a report on Tuesday, October 5th. Finally, Redburn Partners reissued a “sell” rating and issued a $146.00 price objective on shares of BioNTech in a research report on Wednesday, June 16th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $255.36.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.

Read More: Yield Curve

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.